Denali Therapeutics Quarterly Balance Sheet
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 19.49 +0.21%
Denali Therapeutics financial position
As of Jun 30, 2026, Denali Therapeutics reported total assets of $1.16 billion, down 0.7% from a year earlier against total liabilities of $322.8 million. Shareholders' equity stood at $835.2 million, or 72.1% of assets. The company held $201.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.37, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 201.53M | 387.63M | 205.33M | 90.96M | 141.21M | 56.95M | 174.96M | 90.64M | 74.68M | 60.57M | 127.11M | 148.01M |
| Short-Term Investments | 508.94M | 600.06M | 662.55M | 757.24M | 757.75M | 760.98M | 657.37M | 745.92M | 821.37M | 876.29M | 907.40M | 961.25M |
| Receivables | 3.93M | — | 0 | — | — | — | — | — | — | — | — | — |
| Inventory | 4.14M | — | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 753.93M | 1.02B | 900.66M | 882.60M | 934.71M | 878.64M | 864.44M | 868.84M | 928.38M | 973.58M | 1.06B | 1.14B |
| Property, Plant & Equipment | 49.93M | 51.73M | 52.40M | 53.73M | 58.72M | 57.77M | 55.24M | 50.82M | 48.08M | 46.86M | 45.59M | 48.10M |
| Intangible Assets | 35.25M | 36.00M | 0 | — | — | — | — | — | — | — | — | — |
| Long-Term Investments | 229.53M | 63.78M | 98.32M | 24.70M | 78.46M | 235.84M | 359.37M | 445.46M | 450.99M | 490.72M | 0 | 7.91M |
| Total Assets | 1.16B | 1.27B | 1.14B | 1.06B | 1.17B | 1.27B | 1.37B | 1.45B | 1.50B | 1.58B | 1.15B | 1.24B |
| Accounts Payable | 11.81M | 40.38M | 505.00K | 6.75M | 10.84M | 8.46M | 11.14M | 9.59M | 13.94M | 11.86M | 9.48M | — |
| Total Current Liabilities | 90.08M | 110.16M | 98.35M | 90.15M | 91.06M | 91.88M | 102.21M | 87.09M | 74.53M | 82.58M | 77.98M | 71.18M |
| Total Liabilities | 322.78M | 339.93M | 131.09M | 129.42M | 139.19M | 148.66M | 144.50M | 135.52M | 115.51M | 125.62M | 122.96M | 118.45M |
| Shareholders' Equity | 835.18M | 926.10M | 1.01B | 926.20M | 1.03B | 1.12B | 1.23B | 1.32B | 1.39B | 1.46B | 1.03B | 1.12B |
| Retained Earnings | -2.31B | -2.18B | -2.05B | -1.92B | -1.80B | -1.67B | -1.54B | -1.42B | -1.32B | -1.22B | -1.12B | -996.74M |
| Net Cash (Debt) | 710.47M | 987.68M | 867.88M | 848.20M | 898.95M | 817.93M | 832.33M | 836.56M | 896.04M | 936.87M | 1.03B | 1.11B |
| Shares Outstanding | 159.76M | 158.66M | 156.18M | 146.63M | 145.69M | 145.25M | 144.22M | 143.84M | 143.12M | 142.51M | 138.39M | 138.05M |
This table shows 12 quarterly periods of Denali Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a balance sheet?